Nov. 25, 2025 — RapidAI has announced the U.S. Food and Drug Administration (FDA) clearance of five new imaging modules: Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH and Rapid Aortic for measurement. These clearances mark a significant expansion of the Rapid Enterprise Platform, reinforcing RapidAI’s identity as the only platform purpose-built to bring deep clinical intelligence, seamless workflow integration, and secure IT infrastructure to hospitals worldwide.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now